Comparison 3. Liposomal doxorubicin (Caelyx) peak dose 25 mg/m² versus 50 mg/m².

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
3.1 Response rate (defined as objective palliative tumour response (i.e. decrease in PSA levels of >= 50%))	1	48	Risk Ratio (M‐H, Random, 95% CI)	0.07 [0.00, 1.13]
3.2 Adverse effects other than cardiac damage	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
3.2.1 Gastrointestinal toxicity grade 3 or 4	1	48	Risk Ratio (M‐H, Random, 95% CI)	0.17 [0.01, 3.08]
3.2.2 Tachycardia grade 3 or 4	1	48	Risk Ratio (M‐H, Random, 95% CI)	0.06 [0.00, 1.00]
3.2.3 Arrhythmia grade 3 or 4	1	48	Risk Ratio (M‐H, Random, 95% CI)	0.39 [0.04, 3.52]
3.2.4 Dyspnoea grade 3 or 4	1	48	Risk Ratio (M‐H, Random, 95% CI)	0.47 [0.10, 2.20]
3.2.5 Palmar‐plantar erythrodysesthesia grade 3 or 4	1	48	Risk Ratio (M‐H, Random, 95% CI)	5.91 [1.45, 24.16]
3.2.6 Hepatic toxicity grade 3 or 4	1	48	Risk Ratio (M‐H, Random, 95% CI)	0.20 [0.05, 0.79]
3.2.7 Leukopenia grade 3 or 4	1	48	Risk Ratio (M‐H, Random, 95% CI)	0.24 [0.03, 1.87]
3.2.8 Thrombocytopenia grade 3 or 4	1	48	Risk Ratio (M‐H, Random, 95% CI)	0.39 [0.02, 9.15]
3.2.9 Haemoglobin‐related toxicity grade 3 or 4	1	48	Risk Ratio (M‐H, Random, 95% CI)	0.07 [0.00, 1.13]